---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-005405"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2026-08-11T11:00:31+00:00"
generated_at: "2026-08-11T11:05:22.701767+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q2 revenue up 11% to $22.7M; raises FY2026 revenue guidance to 3-5%

## Summary
- Q2 2026 revenue $22.7M, up 11% YoY from $20.5M; FX tailwind of ~1% on constant-currency basis
- Net loss widened to ($2.9)M from ($2.3)M; adjusted EBITDA up to $1.7M from $1.5M
- H1 net loss narrowed to ($6.3)M from ($52.6)M, which included $48.0M Q1 2025 goodwill impairment
- Raises FY 2026 revenue guidance to 3%-5% YoY growth; maintains adjusted EBITDA target
- Growth driven by telemetry and CMT products (AAA, electroporation) plus China demand; H1 operating cash flow ($0.3)M vs $5.7M

## SEC filing metadata
- accession: 0001171843-26-005405
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2026-08-11T11:00:31+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184326005405/0001171843-26-005405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184326005405/f8k_081126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-005405
- JSON: https://secwatch.observer/filing/0001171843-26-005405.json
- Plain text: https://secwatch.observer/filing/0001171843-26-005405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.